Lund, Sweden

Michael Lundkvist

USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 5.3

ph-index = 4

Forward Citations = 62(Granted Patents)


Company Filing History:


Years Active: 2006-2013

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Michael Lundkvist: Innovator in Pharmaceutical Chemistry

Introduction

Michael Lundkvist is a prominent inventor based in Lund, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 10 patents to his name, Lundkvist's work has the potential to impact various medical treatments.

Latest Patents

Among his latest patents, Lundkvist has developed certain 2-pyrazinone derivatives that serve as inhibitors of neutrophil elastase. This invention provides novel compounds, including pharmaceutically acceptable salts, along with processes for their preparation and pharmaceutical compositions containing them. These compounds are particularly useful in therapy as they inhibit human neutrophil elastase. Additionally, he has worked on metalloproteinase inhibitors, specifically compounds that are effective against MMP12.

Career Highlights

Lundkvist is associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on innovative solutions in drug development, contributing to the advancement of medical science.

Collaborations

Throughout his career, Lundkvist has collaborated with notable colleagues, including Pavol Zlatoidsky and Magnus Munck Af Rosenschöld. These collaborations have fostered a productive environment for research and innovation.

Conclusion

Michael Lundkvist's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…